National HIV Testing DayJune 27, 2013
National HIV Testing Day, June 27, promotes the importance of testing in detecting, treating, and preventing human immunodeficiency virus (HIV) infection. HIV testing is the essential entry point to a continuum of prevention, healthcare, and social services that improve the quality of life and the length of survival for persons with HIV (1) . Persons with HIV who receive appropriate treatment, monitoring, and health care also reduce their chances of transmitting HIV to others. CDC recommends that all persons aged 13-64 years be screened for HIV in health-care settings located in areas where the prevalence of undiagnosed HIV infection is >0.1%, and that persons with increased risk for HIV be retested at least annually (2) .
In April 2013, the U.S. Preventive Services Task Force updated its 2005 guidelines on HIV screening, to recommend that clinicians screen all persons aged 15-65 years for HIV infection at least once, regardless of their risk; that younger adolescents and older adults with increased risk also be screened; and that persons with increased risk be screened more frequently (3) . These updated recommendations are based on increasing evidence of the benefits of early antiretroviral therapy for HIV-infected persons and its effectiveness in preventing HIV transmission. Additional information is available at http://www.uspreventiveservicestaskforce.org/ uspstf13/hiv/hivfinalrs.htm#summary, http://www.cdc.gov/ features/hivtesting, and http://www.hivtest.cdc.gov.
The highly infectious phase of acute human immunodeficiency virus (HIV) infection, defined as the interval between the appearance of HIV RNA in plasma and the detection of HIV-1-specific antibodies, contributes disproportionately to HIV transmission (1 (Figure 1) . In retrospective studies, this algorithm performed better than the WB at identifying HIV-antibody-positive persons, detecting acute HIV-1 infections, and diagnosing unsuspected HIV-2 infections (5, 6) . In this report, data from two evaluations of this algorithm are analyzed, one from an HIV testing program in Phoenix, Arizona, and the other from an ongoing HIV testing study in three sites.
In (Table) . The diagnosis of acute HIV infection was established by a negative supplemental test but a detectable HIV-1 RNA in 12 (32.4%) of these 37 patients. The other 25 HIV diagnoses were antibody-positive by Multispot, WB, or both. The median HIV-1 viral load among patients with acute infection was 3,636,176 copies/mL (interquartile range: 614,164 to >10,000,000), compared with 27,125 copies/mL (9,519-78,084) among patients with established infection.
In the STOP study, Architect results were repeatedly reactive in 654 (1.7%) of 37,876 patients screened from September 2011 through September 2012 (Figure 2) . Multispot was reactive for HIV-1 in 554 (84.7%) patients and for both HIV-1 and HIV-2 in one (0.2%). In the 99 (15.1%) patients with a negative or HIV-1 indeterminate Multispot result, HIV-1 RNA was present in 55 (55.6%), representing 8.4% of all those with repeatedly reactive Architect results. Traditional supplemental tests (either HIV-1 WB or IFA) were negative in 37 (67.3%) and indeterminate in seven (12.7%) of these 55 Architect-reactive specimens from patients with acute HIV-1 infection (Figure 2) . 
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to deliver same-day definitive test results to the majority of HIVinfected persons who are antibody-positive. Regardless of which supplemental test is used, clinicians and laboratories might want to consider further HIV RNA testing for patients whose supplemental antibody test results are negative after a reactive third-or fourth-generation IA result (8) .
The ED at Maricopa Integrated Health Systems adopted routine, opt-out HIV screening consistent with CDC's 2006 recommendations (9), using a fourth-generation IA. As a result, an additional 37 patients with HIV infection, including 12 with acute infection, were identified. Because most currently available FDA-approved rapid HIV tests are second-generation format (i.e., they detect only IgG-class antibodies), these acute HIV infections likely would have been missed if point-of-care rapid tests had been used for screening. The high percentage of HIV infections that were acute among these ED patients was unexpected; 
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HIV-2 antibodies detected n = 0 however, consistent with observations that 50%-90% of persons with acute HIV infection develop symptoms that prompt them to seek medical care (10) , this finding suggests that acute HIV infection in persons who seek care for its nonspecific symptoms in EDs and other urgent-care venues might go undiagnosed unless HIV screening is conducted with fourth-generation HIV IAs. Currently, only one RNA assay, the Aptima HIV-1 RNA Qualitative Assay, is FDA-approved for HIV diagnosis, but it is available in far fewer laboratories than quantitative HIV-1 (viral load) RNA assays. To facilitate prompt diagnosis of acute HIV infection when faced with discordant screening and supplemental antibody test results, clinicians can order a viral load test to differentiate acute HIV-1 infection from false-positive IA results. The findings in this report are subject to at least two limitations. First, results might not be generalizable to all HIV screening programs. Although the goal of the Phoenix ED was to screen for HIV as many patients as possible, HIV tests might have been ordered on some patients because of clinical suspicion, potentially increasing the number of HIV or acute HIV infections identified. Second, participants in the STOP study were a convenience sample of persons at high risk for HIV infection attending sexually transmitted infection clinics or communitybased HIV testing programs serving men who have sex with men. Therefore, the percentage of HIV-1 infections that were acute might be higher than that observed in other populations.
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Third-and fourth-generation IAs are important advances for HIV testing that improve the ability to detect HIV infections earlier. In the two prospective evaluations described in this report, the new diagnostic testing algorithm performed better than the current algorithm for identifying HIV infections. CDC's recommendation for a new HIV diagnostic algorithm, which will incorporate the findings of this analysis, is under development. Clinicians can use the findings from this report by remaining vigilant for discordant IA and supplemental test results and either ordering an HIV-1 nucleic acid test or obtaining follow-up HIV testing (in 2-4 weeks) to accurately determine whether HIV infection is present.
